Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.51 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.47 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.43 |
| ▸ | PPARA | Q07869 | 6/20 | 0.42 |
| ▸ | PPARG | P37231 | 5/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.40 |
| ▸ | PPARD | Q03181 | 2/20 | 0.40 |
| ▸ | CTSS | P25774 | 2/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.39 |
| ▸ | ITGAV | P06756 | 1/20 | 0.39 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3011751 | 1.00 | ACE (0.51) | ACEITGA4ITGB7ITGB3ITGA2B | |
| SCHEMBL15650195 | 0.89 | KLK5 (0.44) | ACEITGA4ITGB7CTSSAKT1 | |
| SCHEMBL15650193 | 0.89 | KLK5 (0.44) | ACEITGA4ITGB7CTSSAKT1 | |
| SCHEMBL28029476 | 0.88 | ACE (0.44) | ACEITGA4ITGB7ITGB3ITGA2B | |
| SCHEMBL15998249 | 0.87 | ITGA4 (0.44) | ACEITGA4ITGB7CTSSCTSL | |
| SCHEMBL15649451 | 0.83 | REN (0.39) | ACEITGA4ITGB7CTSSAKT1 | |
| SCHEMBL15649447 | 0.83 | REN (0.39) | ACEITGA4ITGB7CTSSAKT1 | |
| SCHEMBL28029796 | 0.81 | CTSS (0.40) | CTSSAKT1CTSLCTSBCTSK | |
| SCHEMBL1196352 | 0.81 | ACE (0.48) | ACEITGA4ITGB7ITGB3ITGA2B | |
| SCHEMBL1196353 | 0.81 | ACE (0.48) | ACEITGA4ITGB7ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2909197-B1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LTD (GB) | 2020-03-04 | — | — | EP | disclosed |
| US-9663512-B2 | Bicyclic heterocycle compounds and their uses in therapy | ASTEX THERAPEUTICS LIMITED (GB) | 2017-05-30 | — | — | US | disclosed |
| US-20150266873-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2015-09-24 | — | — | US | disclosed |
| EP-2909197-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | Astex Therapeutics Ltd. (GB) | 2015-08-26 | — | — | EP | disclosed |
| CN-104870440-A | Bicyclic heterocycle compounds and their uses in therapy | ASTEX THERAPEUTICS LTD | 2015-08-26 | — | — | CN | disclosed |
| EP-2152664-B1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-09-03 | — | — | EP | disclosed |
| CN-101784516-B | Dipeptide analogs as coagulation factor inhibitors | BRISTOL MYERS SQUIBB CO | 2014-07-02 | — | — | CN | disclosed |
| WO-2014060768-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2014-04-24 | — | — | WO | disclosed |
| US-8367709-B2 | Dipeptide analogs as coagulation factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367709-B2 | Dipeptide analogs as coagulation factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-05 | — | — | US | disclosed |
| CN-101784516-A | Dipeptide analogs as coagulation factor inhibitors | BRISTOL MYERS SQUIBB CO | 2010-07-21 | — | — | CN | disclosed |
| US-20100173899-A1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-07-08 | — | — | US | disclosed |
| US-20100173899-A1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-07-08 | — | — | US | disclosed |
| EP-2152664-A1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | Brystol-Myers Squibb Company (US) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008157162-A1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266873-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | PC, BAD, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | ACE 1088/4885ITGA4 4821/4885ITGB7 4591/4885 |
| US-20100173899-A1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | F11, TFPI, SERPINC1 | ACE 112/4885ITGA4 4230/4885ITGB7 3438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.